These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 31287332

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group, FIXTURE Study Group.
    N Engl J Med; 2014 Jul 24; 371(4):326-38. PubMed ID: 25007392
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN.
    J Eur Acad Dermatol Venereol; 2018 Dec 24; 32(12):2191-2199. PubMed ID: 29729105
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT, Shojania K, Dutz J, Tsao NW.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec 24; 16(2):153-66. PubMed ID: 26681527
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A, Papavassilis C, Bhosekar V, Reinhardt M.
    Drugs Aging; 2018 Feb 24; 35(2):135-144. PubMed ID: 29404966
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.
    Yeh NL, Hsu CY, Tsai TF, Chiu HY.
    Clin Drug Investig; 2019 Dec 24; 39(12):1195-1203. PubMed ID: 31549347
    [Abstract] [Full Text] [Related]

  • 15. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
    Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG.
    J Am Acad Dermatol; 2017 Apr 24; 76(4):655-661. PubMed ID: 28087133
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
    Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G.
    J Eur Acad Dermatol Venereol; 2019 Sep 24; 33(9):1733-1741. PubMed ID: 31009130
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Secukinumab (AIN457) for the treatment of psoriasis.
    López-Ferrer A, Vilarrasa E, Puig L.
    Expert Rev Clin Immunol; 2015 Sep 24; 11(11):1177-88. PubMed ID: 26428036
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.